- /
- Supported exchanges /
- NASDAQ /
- TARS.NASDAQ
Tarsus Pharmaceuticals Inc (TARS NASDAQ) stock market data APIs
Tarsus Pharmaceuticals Inc Financial Data Overview
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Tarsus Pharmaceuticals Inc data using free add-ons & libraries
Get Tarsus Pharmaceuticals Inc Fundamental Data
Tarsus Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 130 M
- EBITDA: -139 458 000
- Earnings Per Share: -3
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-07
- EPS/Forecast: -0.94
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tarsus Pharmaceuticals Inc News
Aggressive Stock Portfolio: 13 Stocks Picked by Analysts
In this article, we will take a look at aggressive stock portfolio: 13 stocks picked by analysts. To skip our analysis of the recent market activity, you can go directly to see the Aggressive Stock Po...
Tarsus Pharmaceuticals, Inc. (TARS) Moves 8.5% Higher: Will This Strength Last?
Tarsus Pharmaceuticals, Inc. TARS shares soared 8.5% in the last trading session to close at $27.98. The move was backed by solid volume with far more shares changing hands than in a normal session. T...
11 Stocks That Will Make You Rich in 5-10 Years
In this article, we will take a detailed look at the11 Stocks That Will Make You Rich in 5-10 Years. For a quick overview of such stocks, read our article 5Stocks That Will Make You Rich in 5-10 Years...
Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade
A Relative Strength Rating upgrade for Tarsus Pharmaceuticals shows improving technical performance. Continue reading
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.